Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used to treat arthritis, menstrual, musculoskeletal and post-operative pain, as well as headache and fever. NSAIDs include acetylsalicylic acid (ASA), traditional NSAIDs (tNSAIDs) (eg, diclofenac, ibuprofen, indomethacin, and naproxen) and inhibitors of the COX-2 isoform of cyclo-oxygenase (referred to here as COX-2s, eg, celecoxib, lumiracoxib, etoricoxib, rofecoxib).
One cohort study found that about 25% of Canadians in 2001 were prescribed short-term NSAIDs (a rise of 28% over 1999 when COX-2s were first introduced), and about 4% were prescribed these agents long-term (defined in this study as 6 months); 1 this equates to approximately 6.2 million short-term users, and 1.0 million long-term users of NSAID therapy. However, this substantially underestimates Rostom et Low-dose ASA is extensively used for cardiovascular risk reduction. There are increasing concerns over the risks of gastrointestinal and cardiovascular adverse events with these medications. The increased risks of upper gastrointestinal ulcers and complications with tNSAIDs and ASA are well documented, [3] [4] [5] [6] [7] and while the risks are reduced by about 50% with COX-2s, they continue to be important since this risk is not reduced to baseline. [8] [9] [10] Furthermore with the introduction of COX-2s in the late 1990, overall NSAID prescriptions rose with COX-2s overtaking tNSAIDs suggesting that individuals not previously on NSAIDs were being prescribed COX-2s. Over the same time frame, there was a 75.9% increase in the rate of non-fatal digestive perforations and hemorrhages in the presence of NSAIDs. Moreover, the benefits of COX-2s are attenuated when COX-2s are co-prescribed with ASA 10 although to a lesser extent than when tNSAIDs are co-prescribed with ASA. In addition, extensive data associate COX-2s and nonnaproxen tNSAIDs with an increased risk of cardiovascular events, 11, 12 which has led regulatory authorities to introduce warning statements and advisories Additionally, the COX-2s, rofecoxib, valdecoxib, and lumiracoxib have been withdrawn from the market because of cardiovascular, cutaneous, and hepatic adverse events respectively. 1, 2, [13] [14] [15] Health Canada and the Food and Drug Administration (FDA) require the product information for tNSAIDs and COX-2s to include a warning of the increased incidence of cardiovascular (eg, heart attack, stroke) and gastrointestinal (eg, ulcer, bleeding) adverse events, as well as recommendations to limit use of the drug to the lowest effective dose for the shortest possible duration of treatment. 2, 15 The purpose of this study was to systematically review the literature on interventions to prevent tNSAID related upper gastrointestinal (GI) toxicity, and on the GI safety of COX-2s.
Methods
This review was conducted in accordance with the methods of the Cochrane Collaboration. 16 
Literature search strategy
The search strategy and methods have been previously described elsewhere. These were updated to May 2009. 10, 17 inclusion criteria Types ]) were considered eligible for inclusion if the upper GI toxicity of these agents was compared to that of a non-selective NSAID or to placebo. RCTs of prostaglandin analogues (misoprostol), H 2 -receptor antagonists (H2RA), and proton pump inhibitors (PPI) in the prevention of NSAID-induced upper GI toxicity were also considered if these agents were used alongside an NSAID compared to an NSAID alone. Further the RCTs had to meet the following additional criteria.
Participants were 18 years or older and had osteoarthritis, rheumatoid arthritis or another arthritic condition; NSAID exposure was 4 weeks or longer (chronic NSAID exposure); the proportion of patients with endoscopic ulcers, significant clinical GI events (eg, perforation, obstruction, bleeding, symptomatic ulcers), and/or symptom based clinical events (adverse GI symptoms, withdrawals due to GI symptoms) could be determined; endoscopic ulcers were defined as being at least 3 mm in diameter or could be distinguished from erosions based on the authors' descriptions; and it was noted whether endoscopy was performed based on symptoms or as part of a protocol.
Types of interventions
The interventions included the following COX-2s: celecoxib (Celebrex ® ), rofecoxib (Vioxx ® ), etoricoxib (Arcoxia ® ), valdecoxib (Bextra ® ), lumiracoxib (Prexige ® ). For this review, low-dose COX-2s were defined as celecoxib 200 mg bid or less, rofecoxib 25 mg daily or less, etoricoxib 60 mg daily or less, valdecoxib 10 mg daily or less, and lumiracoxib 100 to 200 mg. High-dose COX-2s were defined as celecoxib 400 mg bid, rofecoxib 50 mg daily, etoricoxib 90 mg daily or more, valdecoxib 20 mg daily or more, and lumiracoxib 400 mg or more. For prophylaxis against tNSAID induced upper GI toxicity we included: the prostaglandin antagonist misoprostol (Cytotec ® ) (low dose 400 µg/day, intermediate dose 600 µg/day; high dose 800 µg/day); the PPIs omeprazole, esomeprazole, pantoprazole, and lansoprazole (Losec ® , Nexium ® , Pantoloc ® , Prevacid ® , respectively); and the H2RAs cimetadine, ranitidine, nizatidine, and famotidine (Tagamet ® , Zantac ® , Axid ® , and Pepcid ® , respectively). Double doses of H2RAs were defined as a dose equivalent to or greater than 300 mg of ranitidine twice daily, and standard dose of PPIs were considered the equivalent of 20 mg of omeprazole once daily.
Statistical analysis
Data were analyzed using Review Manager (RevMan) version 5.0. Endoscopic, clinical and symptom-based outcomes were analyzed separately. The primary analyses were expressed as relative risks using a fixed effects model. A random-effects model was used to combine "heterogeneous trials" only if it was clinically and statistically appropriate. The absolute risk reduction (ARR ) was calculated for appropriate clinical endpoints.
Subgroup analyses
Studies were grouped by interventions (eg, COX-2s vs tNSAIDs, and COX-2s vs placebo), dosage (low-dose and high-dose), and duration of therapy. Additionally, within each of the three main outcome analyses (endoscopic ulcer, clinical ulcer, and symptoms), studies were analyzed as all COX-2s vs all tNSAIDs, individual COX-2s vs all comparator tNSAIDs, individual tNSAIDs vs all comparator COX-2s, and individual COX-2s vs individual tNSAIDs.
Heterogeneity
Sources for clinical and statistical heterogeneity were sought prior to statistical analyses. Logical analyses subgroups were created (see above) to allow for more homogeneous analyses groups. Heterogeneity was tested using the I 2 statistic and a chi-square test. An I 2  50% or a chi-square p value of less than 0.10 is considered to be evidence of statistical heterogeneity. 20 
Sensitivity analyses
In addition to the published reports, unique studies were identified from the FDA web site, and in the form of published "combined analyses" studies. The latter studies combined published and unpublished primary patient data from the endoscopic studies, as well as the safety and tolerability studies to allow sample sizes large enough to comment on clinical ulcer complications. We carefully examined these studies by their ID number, their sample size, patient demographics and list of authors and cross referenced with the FDA web site in order to ensure that their use in the ulcer complication analyses would not create duplication of individual patient data. Sensitivity analyses were conducted removing or adding FDA studies, and the combined analyses studies. Additionally, sensitivity analyses were used to assess the impact of supplemental FDA data on published study results when available (eg, CLASS study). Sensitivity analysis was also performed removing studies with quality scores of 2 or less.
Results

Part i -tNSAiD prophylaxis
Of a total of 1205 references with 256 being potentially relevant, 39 RCTs met the inclusion criteria: 23 misoprostol trials (includes 6 head to head studies); 12 H2RA (9 standard dose, 3 double dose, 1 head to head); and 9 PPI trials (6 direct, 5 head to head). Some studies considered more than one active intervention. Table 1 summarizes the characteristics of the included studies. Effects of interventions are summarized below.
Misoprostol
We found 23 studies that assessed the long term effect of misoprostol on the prevention of tNSAID ulcers. 14, endoscopic ulcers Eleven studies with 3,641patients compared the incidence of endoscopic ulcers, after at least 3 months, of misoprostol to that of placebo. 21, 22, 25, [29] [30] [31] [32] [33] 36, 38, 42 The cumulative incidence of endoscopic gastric and duodenal ulcers with placebo were 15% and 6% respectively. Misoprostol (any dose combined) significantly reduced the relative risk of gastric ulcer and duodenal ulcers by 74% relative risk [RR] and 58% (RR 0.42; 95% CI 0.22 to 0.81, random effects). These relative risks correspond to a 12.0%, and 3% absolute risk reductions for gastric and duodenal ulcers respectively. The observed heterogeneity in these estimates was due to inclusion of all misoprostol doses in the analyses. Analysis of the misoprostol studies stratified by dose eliminated this heterogeneity.
Analysis by dose
All the studied doses of misoprostol significantly reduced the risk of endoscopic ulcers, and a dose response relationship was demonstrated for endoscopic gastric ulcers. Six studies with 2,461 patients used misoprostol 400 µg. 22, 25, 30, 33, 36, 42 1 study with 928 patients used 600 µg daily, 36 and 7 with 2,423 patients used 800 µg daily. 21, [29] [30] [31] [32] 36, 38 Misoprostol 800 µg daily was associated with the lowest risk (RR 0.17; 95% CI 0.11 to 0.24) of endoscopic gastric ulcers when compared to placebo, whereas misoprostol 400 ug daily was associated with a relative risk of 0.42 (95% CI 0.28 to 0.67, random effects model for heterogeneity) (Figure 1 ).
This difference between high-and low-dose misoprostol reached statistical significance (P0.0055). The intermediate misoprostol dose (600 µg daily) was not statistically different from either the low or high dose. The pooled relative risk reduction of 78% (4.7% absolute risk difference, RR 0.21; 95% CI 0.09 to 0.49) for duodenal ulcers with misoprostol 800 µg daily was not statistically different from those of the lower daily misoprostol dosages.
Studies including data with less than 3 months tNSAiD exposure
Eight studies, with 2,206 patients, assessed the rates of endoscopic ulcers with misoprostol compared to placebo at 1 to 1.5 months. 14, 23, 24, 26, 28, 29, 34, 39 The pooling of these studies revealed an 81% relative risk reduction of gastric ulcers with misoprostol (RR 0.17; 95% CI 0.09 to 0.31) and an 72% relative risk reduction of duodenal ulcers (RR 0.28; 95% CI 0.14 to 0.56).
One study compared misoprostol to a newer cytoprotective agent, dosmafate, for tNSAID prophylaxis and found no statistically significant difference in ulcer rates between the two agents. 27 
Clinical ulcers
Only 1 RCT, the MUCOSA trial, evaluated the efficacy of misoprostol prophylaxis against clinically important TNSAID induced ulcer complications as the powered primary endpoint. In this study, of 8,843 patients studied over 6 months, the overall GI event incidence was about 1.5% per year. 40 Misoprostol 800 µg/day was associated with a statistically significant 40% risk reduction (odds ratio0.598; 95% CI 0.364 to 0.982) in combined GI events (P0.049), representing a risk difference of 0.38% (from 0.95% to 0.57%).
Adverse effects
Misoprostol was associated with a small but statistically significant 1.6 fold excess risk of drop out due to drug induced side effects, and an excess risk of drop-outs due to nausea (RR 1.30; 95% CI 1.08 to 1.55), diarrhea (RR 2.36; 95% CI 2.01 to 2.77), and abdominal pain (RR 1.36; 95% CI 1.20 to 1.55). In the MUCOSA trial, 732 out of 4,404 patients on misoprostol experienced diarrhea or abdominal pain, compared to 399 out of 4,439 on placebo for a relative risk of 1.82 associated with misoprostol (P  0.001). Overall 27% of patients on misoprostol experienced one or more side effects. 40 When analyzed by dose, only misoprostol 800 µg daily showed a statistically significant excess risk of drop-outs due to diarrhea (RR 2.45; 95% CI 2.09 to 2.88), and abdominal pain (RR 1.38; 95% CI 1.17 to 1.63 ). Both misoprostol doses were associated with a statistically significant risk of diarrhea. However, the risk of diarrhea with 800 µg/day (RR 3.25; 95% CI 2.60 to 4.06) was significantly higher than that seen with Prevention of NSAiD-related upper Gi toxicity Dovepress submit your manuscript | www.dovepress.com Dovepress 400 µg/day (RR 1.81 95% CI 1.52 to 2.16) (P0.0012). The results for overall dropouts due to symptoms analyzed by dose are shown in Figure 2 .
H2RAs
Seven trials with over 900 patients assessed the effect of standard dose H2RAs on the prevention of endoscopic tNSAID ulcers at 1 month, [43] [44] [45] [46] [47] [48] and 5 trials with 1,005 patients assessed these outcomes at 3 months or longer. 44, 47, [49] [50] [51] Standard dose H2RAs are effective at reducing the risk of duodenal ulcers (RR 0.24; 95% CI 0.10 to 0.57, and RR 0.36; 95% CI 0.18 to 0.74 at 1 and 3 or more months respectively), but not of gastric ulcers (NS). One study did not have a placebo comparator and was not included in the pooled estimate. 51 Three RCTs with 298 patients assessed the efficacy of double dose H2RA for the prevention of tNSAID induced upper GI toxicity. 47, 52, 53 Double-dose H2RAs when compared to placebo were associated with a statistically significant reduction in the risk of both duodenal (RR 0.26; 95% CI 0.11 to 0.65) and gastric ulcers (RR 0.44; 95% CI 026 to 0.74). This 56% relative risk reduction in gastric ulcer corresponds to a 12% absolute risk difference (from 23.1% to 11.3%) ( Figures 3 and 4) . Analysis of the secondary prophylaxis studies alone yielded similar results.
Symptoms
H2RA, in standard or double doses, were not associated with an excess risk of total drop-outs, dropouts due to side effects, 
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PPis
Six RCTs with 1,259 patients assessed the effect of PPIs on the prevention of NSAID-induced upper GI toxicity. 32, 33, [54] [55] [56] [57] PPIs significantly reduced the risk of both endoscopic duodenal (RR 0.20; 95% CI 0.10 to 0.39) and gastric ulcers (RR 0.39; 95% CI 0.31 to 0.50) compared to placebo (Figures 5 and 6) . 32, 33, [54] [55] [56] [57] The results were similar for both primary and secondary prophylaxis trials.
Symptoms
Four omeprazole trials used the same composite endpoints to define treatment success. 33, 55, 56, 58 In these trials omeprazole significantly reduced "dyspeptic symptoms" as defined by the authors. In the combined analysis, drop-outs overall 
Head to head comparisons of gastroprotective agents Misoprostol vs H2RAs
Two trials with 600 patients compared misoprostol (400 to 800 µg) to ranitidine 150 mg twice daily. 36 , 41 Misoprostol appears superior to standard dose ranitidine for the prevention of tNSAID induced gastric ulcers (RR 0.12; 95% CI 0.03 to 0.51) but not for duodenal ulcers (RR 1.00; 95% CI 0.14 to 7.14).
PPi vs H2RAS
Yeomans et al in a 12-week study of 425 patients, compared omeprazole 20 mg daily to ranitidine 150 mg twice daily for tNSAID prophylaxis (various tNSAIDs used). 58 In this study, omeprazole was superior to standard-dose ranitidine for the prevention of both gastric (RR 0.32; 95% CI 0.17 to 0.62) and duodenal ulcers (RR 0.11; 95% CI 0.01 to 0.89).
PPi vs misoprostol
Four trials with a total of 1,478 patients 13 
Symptoms
In the two head to head comparison of omeprazole and misoprostol, 32, 33 PPIs were associated with significantly less drop-outs overall (RR 0.71; 95% CI 0.52 to 0.97), as well as significantly less drop-outs due to side effects (RR 0.48; 09% CI 0.29 to 0.78). Compared to H2RA used for less than 2 months, misoprostol caused significantly more drop-outs due to abdominal pain (RR 3.00, 95% CI 1.11 to 8.14) and more symptoms of diarrhea (RR 2.03, 95% CI 1.38 to 2.99). There were no significant differences in drop-outs due to 
Study or Subgroup
Part II -COX-2 inhibitors
The search strategy identified 1,169 studies. Of these, 255 references were rated as potentially relevant and the full articles were retrieved. Sixty studies met the inclusion criteria, including 4 unique studies obtained from the new drug submission documents on the FDA web site.
59-63
An additional 5 "combined analyses studies" were identified by the search strategy and were included for the clinical ulcer complication endpoint (Table 2) . [64] [65] [66] [67] [68] Quality scores of the 60 included trials ranged between 4 to 5 in 47 and between 2 to 3 in 22 studies. Removal of quality score 2 studies did not influence overall results. The use of allocation concealment was implied in all of the included trials, but was adequately described in only 6 studies.
Endoscopic ulcers were the measured endpoints of 17 studies.
59-61,63,69-81 Eleven COX-2 studies, 78,82-91 and 5 combined analyses [65] [66] [67] [68] 92 reported on the outcome of clinical GI events (POBs or PUBs).
The remaining trials were either safety or tolerability studies or examined the clinical efficacy of COX-2s compared to tNSAIDS, but allowed for extraction of GI tolerability data. 62, 67, 88, [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] FDA study data are only presented as part of sensitivity analyses. Results specifically pertaining to meloxicam are not included herein.
endoscopic ulcer trials CoX-2s vs non-selective NSAiDs
Seventeen studies with over 10,000 patients assessed the proportion of patients who developed endoscopic ulcers while taking a COX-2 compared to those taking a tNSAID. 75, 81 Some studies assessed more than one intervention. 75, 81 endoscopically detected gastro-duodenal ulcers Thirteen studies with a total of 7,839 patients showed a 74% relative risk reduction (RRR ) in combined gastro-duodenal ulcers with COX-2s vs tNSAIDs (RR 0.26; 95% CI 0.23 to 0.30). [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] 112 This represented a 16% absolute risk reduction (ARR). Addition of the FDA studies did not significantly alter the results (RR 0.28; 95% CI 0.24 to 0.32). The results analyzed by the dose of COX-2s gave similar results. Results below are for "any dose" combined.
Eleven studies with a total of 6,726 patients compared the safety of a COX-2 to a comparator tNSAID for endoscopic gastric ulcers. [69] [70] [71] [72] [73] [74] [75] [76] [77] 80, 112 The use of a COX-2 in this setting was associated with a 79% RRR in gastric ulcers (RR 0.21; 95% CI 0.18 to 0.25) (Figure 7 ). This represented a 14% ARR in gastric ulcers with the use of COX-2s compared with tNSAIDs. Addition of the FDA studies did not significantly alter the results (RR 0.26; 95% CI 0.22 to 0.30).
The same 11 studies also compared the proportions of duodenal ulcers that occurred while using a COX-2 vs a tNSAID. [69] [70] [71] [72] [73] [74] [75] [76] [77] 80, 112 Compared to using a tNSAID, the use of a COX-2 was associated with a 66% RRR in duodenal ulcers (RR 0.34; 95% CI 0.25 to 0.45) (Figure 7 ). This represented a 3% ARR. Addition of the FDA studies did not significantly alter the results (RR 0.29; 95% CI 0.23 to 0.38) Keeping in mind that tNSAID related gastric ulcers were more commonly observed than duodenal ulcer, a trend was observed for greater RRR and ARR in gastric ulcers than for duodenal ulcers with COX-2s, compared to tNSAIDs (RR 0.21 vs 0.34, ARR of 14% vs 3%). This trend was consistent when celecoxib, rofecoxib and valdecoxib were analyzed separately. Analysis by duration The data presented above are for any dose and duration up to 6 months. Subgroup analysis of these studies on the basis of duration (1 to 3 months and 3 to 6 months) did not significantly alter the results.
Analysis by COX-2
Analyses stratified by the individual COX-2s showed that each of the studied agents were safer than comparator tNSAIDs (Figure 8 ).
Celecoxib
Five studies with a total of 2,439 patients compared celecoxib to non-selective NSAIDs, showing a 79% RRR in total gastro-duodenal ulcers (RR 0.21; 95% CI 0.16 to 0.28) with celecoxib. [69] [70] [71] 75, 112 Similar RRR were observed for gastric ulcers (RR 0.20; 95% CI 0.14 to 0.28) and duodenal ulcers alone (RR 0.29; 95% CI 0.18 to 0.47), as well as when the FDA studies were included (RR 0.26; 95% CI 0.21 to 0.32).
Rofecoxib
Three studies with a total of 1,526 patients compared rofecoxib to non-selective NSAIDs. [72] [73] [74] In this case, a 74% RRR was seen with rofecoxib (RR 0.26; 95% CI: 0.21 to 0.32). The results were similar when FDA studies were added to the analysis as well as when the analysis was done only for gastric ulcers (RR 0.20; 95% CI 0.15 to 0.26) and duodenal ulcers alone (RR 0.36; 95% CI 0.14 to 0.93, random effects). 
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Dovepress etoricoxib
Two studies, with a total of 900 patients compared etoricoxib to non-selective NSAIDs using the endpoint of endoscopic gastro-duodenal ulcers. 78, 79 These trials demonstrated a 64% RRR (RR 0.37; 95% CI 0.18 to 0.77, random effects) with etoricoxib.
valdecoxib Three studies compared valdecoxib to non-selective NSAIDs in 2,045 patients and demonstrated a 70% RRR in gastro-duodenal ulcers (RR 0.29; 95% CI 0.21 to 0.39) with valdecoxib. 76, 77, 80 Similar RRR were observed when the analysis was done for gastric ulcers (RR 0.24; 95% CI 0.18-0.37) and duodenal ulcers alone (RR 0.39; 95% CI 0.21 to 0.70), and when the FDA studies were included in the gastro-duodenal ulcers analysis (RR 0.30; 95% CI 0.24 to 0.39).
Lumiracoxib
Two studies with a total of 1,376 patients compared lumiracoxib to non-selective NSAIDs. 112, 113 Lumiracoxib was 
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Total events Heterogeneity: Chi² = 0.00, df = 1 (P = 0.98); I² = 0% Test for overall effect: Z = 6.72 (P < 0.00001) Results were similar when the FDA studies were included in the analysis (RR 0.28; 95% CI 0.23 to 0.32).
Diclofenac
Three studies which enrolled a total of 1,596 patients demonstrated a 75% RRR in gastro-duodenal ulcers with COX-2s compared to diclofenac (RR 0.25; 95% CI 0.18 to 0.35). This effect was somewhat reduced when the FDA studies were included in the analysis (RR 0.36; 95% CI 0.27 to 0.47). 70, 76, 77 Similar results were obtained when individual COX-2s were compared with the individual non-selective NSAIDs.
COX-2s vs placebo
Eight studies with a total of 4,081 patients compared low-and high-dose COX-2s to placebo. [71] [72] [73] [74] 76, [78] [79] [80] Low dose COX-2s appeared to demonstrate no greater risk of gastric or gastro-duodenal ulcers than placebo. However, high doses of COX-2s appeared to raise the relative risk of gastric (RR 1.22; 95% CI 0.83 to 1.80), duodenal (RR 1.29; 95% CI 0.63 to 2.66), and combined gastro-dudenal ulcers (RR 1.57; 95% CI 0.96 to 2.56, random effects), though these trends missed statistical significance. Clinical GI events COX-2s vs non-selective NSAIDs Nine studies with a total of 94,294 patients assessed the safety of COX-2s by using the clinically important endpoint of ulcer complication, POB. 65, 66, 68, 82, 83, 92, [114] [115] [116] Three of these trials studied celecoxib, 82 114 separately. Overall, the use of these COX-2s was associated with a 57% RRR in POBs (RR , 0.43; 95% CI 0.28 to 0.67, random effects), compared with using tNSAIDs. Removal of the combined analyses studies had no influence on the result (RR 0.39; 0.29 to 0.53) and the inclusion of the FDA 12-month CLASS study data 117 did not alter the results (RR 0.42; 95% CI 0.33 to 0.54). The 60% RRR in these analyses represents an ARR of 0.4% (Figure 9) .
Fourteen studies compared COX-2s with tNSAIDs by using PUB as the study endpoint. 65, 66, 68, 78, 82, 83, [87] [88] [89] [90] 92, [114] [115] [116] In this analysis, the use of a COX-2 was associated with a 57% RRR in PUBs (RR 0.43; 95% CI 0.34 to 0.55, random effects). Removal of the combined analyses studies eliminated the observed heterogeneity but had little effect on the point estimate (RR 0.49; 95% CI 0.41 to 0.58). Similarly, the use of the FDA CLASS data did not significantly alter the estimate (RR 0.42; 95% CI 0.33 to 0.53, random effects) (Figure 10 ).
Analyses stratified by cyclooxygenase-2s
Celecoxib Four studies with 31,106 assessed the effect celecoxib vs non-selective NSAIDs on clinical GI events (POBs or PUBs). 82, 89, 92 Celecoxib use was associated with a 77% RRR in POBs (RR 0.23; 95% CI 0.07 to 0.76, random effects) and a 61% RRR in PUBs (RR 0.39; 95% CI 0.21 to 0.73, random effects). Removal of the combined analyses study 92 eliminated the heterogeneity observed in both the POB (RR 0.42; 95% CI 0.22 to 0.80) and PUBs (RR = 0.34; 95% CI 0.22 to 0.80) analyses. The use of the FDA 12-month CLASS data did not alter the RR estimates for POBs or PUBs significantly.
Rofecoxib
Four studies with 19,288 patients assessed the effect of rofecoxib vs non-selective NSAIDs on clinical GI events (POBs or PUBs). 66, 83, 88, 90 Rofecoxib use reduced the relative risk of POBs by 58% (RR 0.42; 95% CI 0.24 to 0.73) and the relative risk of PUBs by 56% (RR 0.44; 95% CI 0.34 to 0.58). Removal of the combined analysis study did not alter the point estimates.
valdecoxib One combined analysis study with 6,461 patients evaluated the effect of valdecoxib on POBs and PUBs. 65 Valdecoxib reduced the relative risk of POBs by 65% (RR 0.35; 95% CI 0.14 to 0.87) and the relative risk of PUBs by 77% (RR 0.23; 95% 0.15 to 0.36). 
Lumiracoxib
One study with 18,244 patients demonstrated a significant 64% RRR in POBs (RR 0.36; 95% CI 0.24 to 0.55) and a 44% RRR in PUBs (RR 0.56; CI 0.41 to 0.78) with the use of lumiracoxib, compared with using non-selective NSAIDs. 114 
Analysis by comparator NSAiDs
In general COX-2s appeared to maintain their safety advantage regardless of the comparator non-selective NSAID. COX-2s were statistically superior to naproxen (RR 0.34; 95% CI 0.24 to 0.48), and ibuprofen (RR 0.46; 95% CI 0.30 to 0.71) for the POB endpoint. The data comparing COX-2s to diclofenac are predominately derived from 2 studies and heavily influenced by the CLASS trial data which showed no significant difference between celecoxib vs diclofenac. 82, 92 In the current analysis, celecoxib demonstrated a non-significant trend towards fewer POBs than diclofenac (RR 0.31; 95% CI 0.06 to 1.61) while a statistically significant 59% RRR in PUBs was observed (RR 0.41; 95% CI 0.30 to 0.55). 
Study or Subgroup
Dovepress
COX-2s vs placebo
There are limited data, mostly derived from the combined analyses studies, comparing COX-2s with placebo for the clinical outcomes of POBs 65, 92 and PUBs. 65, 66, 87, 89, 92 In these analyses, the use of COX-2s was associated with non-significant trends toward an increased RR of POBs (RR 2.66; 95% CI 0.34 to 20.95) and PUBs (RR 2.26; 95% CI 0.96 to 5.33) (Figure 9 ). These findings are supported by the APPROVe polyp prevention study which demonstrated that over a 3-year period, rofecoxib was associated with a statistically significant 4.9-fold increased risk of clinical ulcer complications compared to placebo. 9 This study was not included in the main results since its population did not include arthritis patients.
Influence of acetylsalicylic acid co-administration on clinically important ulcer complications
Five trials allowed assessment of the effects of the co-administration of ASA with a COX-2. 65, 82, 91, 114, 116 In a pooled subgroup analysis of over 18,000 patients taking ASA, there was no statistically significant difference in the relative risk of ulcer complications (POBs) between those in the COX-2 arms and those in the non-selective arms of these trials (RR 0.93; 95% CI 0.68 to 1.27 for POBs). A small advantage of COX-2s over tNSAIDs cannot be ruled out by these results because this subgroup analysis might be underpowered The PUB analysis showed a statistically significant benefit for COX-2 + ASA vs tNSAID +ASA (RR 0.72; 95% CI 0.62 to 0.95), but data from one study could not be used in this analysis. In more than 40,000 patients in the COX-2 arms, patients taking ASA had a 3.46 (95% CI 2.44 to 4.91) greater relative risk of POBs than COX-2 users not taking ASA. Among 34,000 patients in the tNSAID arms of these studies, those taking ASA had a 1.65 greater relative risk of POBs than those not taking ASA, although this result did not reach statistical significance (95% CI 0.76 to 3.57). One must keep in mind that these are post-hoc subgroup analyses that might be subject to bias. Furthermore, the subgroup analysis within an tNSAID treatment group (eg, COX-2 vs COX-2 + ASA) represents a nonrandomized comparison in which differences could be influenced by factors other than ASA use (Figures 11 to 13 ).
Addition of a PPi to COX-2s
The comparative safety of a COX-2s compared to a tNSAID with a PPI has been addressed in high-risk patients with recent ulcer bleeding who were enrolled after ulcer healing and H. pylori eradication. Chan et al 118 found recurrent ulcer bleeding at 6 months to be 4.9% with celecoxib 200 mg twice daily and 6.4% with diclofenac 75 mg twice daily plus omeprazole 20 mg daily. Lai et al 119 found recurrent ulcer complications (bleeding and 1 case of severe pain) in 3.7% with celecoxib 200 mg daily and 6.3% with naproxen 750 mg daily plus lansoprazole 30 mg daily at a median follow-up of 24 weeks. These results suggest high-risk patients have high rates of recurrent bleeding even with the protective strategy of a coxib or a tNSAID + PPI.
The combination of a coxib and PPI was assessed in the same high-risk population in a subsequent 1-year study by Chan et al 120 Recurrent ulcer bleeding occurred in 9% with celecoxib alone vs zero with celecoxib plus twice daily esomeprazole. The MEDAL Program also demonstrated that a coxib plus PPI had significantly fewer upper GI clinical events (again, driven by a decrease in uncomplicated events) than a tNSAID plus PPI (RR 0.62, 0.45 to 0.83). 116 
Symptoms and treatment withdrawals
Treatment withdrawals as a result of GI side effects: COX-2s vs nonselective NSAIDs.
Twenty-one studies with close to 47,000 patients assessed the effect of COX-2s on patient withdrawals due to GI symptoms. 61, [69] [70] [71] 79, 82, 83, [87] [88] [89] [90] 95, 98, 101, 106, 109, 110, 111, 115, [121] [122] [123] Overall, compared to tNSAIDs, COX-2s were associated with a significantly lower relative risk of withdrawals due to GI Prevention of NSAiD-related upper Gi toxicity Dovepress submit your manuscript | www.dovepress.com Dovepress side effects (RR 0.65; 95% CI 0.57 to 0.73, random effects), withdrawals due to dyspepsia (RR 0.37; 95% CI 0.18 to 0.74), and due to abdominal pain (RR 0.25; 95% CI 0.13 to 0.49). Compared to placebo, low-dose COX-2s showed no statistically significant difference for these same endpoints, while high-dose COX-2s were associated with a small but significantly increased relative risk of drop-outs due to GI side effects (RR 1.74; 95% CI 1.13 to 2.68).
Adverse Gi symptoms with COX-2s compared with non-selective NSAiDs
Twenty-eight studies with close to 60,000 patients assessed the effect of low-or high-dose COX-2s compared to tNSAIDs for treatment related overall GI side effects, dyspepsia, nausea, and abdominal pain. 69 
Discussion
The results of this systematic review demonstrate that there are several therapeutic strategies available to reduce the incidence of tNSAID related upper GI harms. Large, well powered, studies have shown that strategies using a tNSAID with misoprostol, or the use of a COX-2 instead of a tNSAID, each reduce the incidence of endoscopically detected upper GI ulcerations, and clinically important upper GI events such as bleeding. Misoprostol in doses that prevent upper GI ulcer complications is associated with important adverse effects which may limit its long-term use. Standard doses of H2RAs reduce the incidence of duodenal ulcers but are not effective at reducing the incidence of gastric ulcers. Double doses of H2RAs and standard-dose PPIs reduce the incidence of duodenal as well as gastric ulcers, but because tachyphylaxis can occur with chronic H2RA use, a standard-dose PPI Dovepress strategy is preferred. H2RAs and PPIs have not been directly assessed in large primary prevention clinical outcome studies powered to detect ulcer complications. However, in secondary prevention studies of high-risk GI patients, tNSAIDs with a PPI appear as effective as a COX-2 strategy at preventing clinical ulcer complications. In these high-risk patients, these strategies were still associated with important ulcer relapse rates, suggesting that both strategies may provide incomplete protection for the secondary prevention of tNSAID-related ulcers. However, a recent study has shown that a strategy of combining a PPI with a COX-2 was superior to a COX-2 alone for the secondary prevention of ulcer complications, suggesting that a COX-2 + PPI strategy is the preferred strategy in high-risk GI patients. Further, the current metaanalysis, supported by the APPROVe polyp prevention study, 9 has shown that while COX-2 offer greater GI safety than tNSAIDs as a group, COX-2 are associated with a statistically greater risk of clinical upper GI complications than those taking placebo. The discovery that COX-2s are associated with important cardiovascular harm has complicated the clinical use of NSAIDs significantly. Further, in Canada, all COX-2 save celecoxib have been withdrawn from the market due to cardiovascular and other harms and it is unlikely that a new COX-2 would be released to market unless it is truly cardiovascularly neutral or it is combined with a GI-safe antithrombotic agent. During this time of uncertainty, when physicians were actively switching patients back to tNSAIDs + a gastropropective agent such as a PPI, it became increasingly clear that non-naproxen tNSAIDs were also associated with important CVS harms.
11 A meta-analysis by Kearney et al using an extensive set of RCT data derived from published and unpublished studies has suggested that, as a group, COX-2s are associated with an increased risk of CV outcomes when compared with placebo or naproxen, but not when compared with non-naproxen, non-ASA tNSAIDs 11 suggesting that non-naproxen-tNSAIDs share the cardiovascular harms of COX-2s.
In light of the cardiovascular harm data relating to COX-2s, it is tempting to suggest combining these agents with ASA. However, the available data from this metaanalysis suggest that this strategy would likely undermine the GI safety advantage of COX-2s. In patients taking ASA, we found no statistically significant difference in POBs or PUBs in patients randomized to a COX-2 or a tNSAID; however, the analyses did not stratify the randomization for ASA use. Thus, it is possible that other patient-related factors played a role in this result. Furthermore, although the analysis included about 7000 patients, it is still possible that a protective effect of COX-2s over tNSAIDs in this setting is present but not detected because of insufficient statistical power. We also found that the addition of ASA to a COX-2 significantly increased the risk of a POB 4.12-times over a COX-2 alone, and that the addition of ASA to a tNSAID demonstrated a nonsignificant 1.27 increased risk of POBs over the use of a tNSAID alone. One needs to note that these analyses represent nonrandomized comparisons, and that the group sizes were somewhat uneven (more patients in the COX-2 or tNSAID alone groups than in the groups with ASA). Nonetheless, the results are not entirely unexpected, because it has been known for some time that concomitant use of multiple NSAIDs increases the risk of GI complications over a single NSAID alone. These results are also in keeping with an RCT by Laine et al 127 revealing that the incidence of endoscopically detected ulcers with rofecoxib and low-dose ASA was not lower than that seen with ibuprofen alone. However, it is clear that further study in this area is required to verify the above findings, such as through a dedicated RCT or from individual patient data systematic reviews. Further, adding ASA to a COX-2 implies that the COX-2s will not interfere with the effect of ASA. However, this hypothesis also requires further study because there are suggestions that the use of a tNSAID might interfere with the action of ASA in this setting, although there appears to be less interference with selective COX-2s. [128] [129] [130] [131] [132] When COX-2s were released, they promised an era of improved GI safety, as well as an era of greater clinical simplicity, with the option of prescribing a single low risk agent when chronic NSAID use was required. However, with the greater understanding of the GI, cardiovascular, and other end organ safety profile of tNSAIDs and COX-2s, clinicians must now stratify their patients on the basis of GI, cardiovascular, and other organ system risk factors and choose an NSAID strategy, that minimizes a patient's overall risk. This has become especially difficult, for patients who are know to be at high risk of GI and cardiovascular harms.
When considering the treatment of an arthritic patient with a tNSAID or a COX-2, a clinician must consider the patient`s underlying GI, cardiovascular, and other organ risks factors. Further, low-dose ASA is recommended for patients at increased cardiovascular risk; 133, 134 therefore an algorithm considering-high cardiovascular risk patients needs to assume the use of low-dose ASA in such patients. The recent Canadian Consensus Conference on NSAIDs proposed the following recommendations; 135 For patients with both low GI and cardiovascular risk, a tNSAID alone may be acceptable.
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For patients with low GI risk and high cardiovascular risk, naproxen may be preferred because of the potential lower cardiovascular risk than with other tNSAIDs or COX-2s. However, since these patients are assumed to be on low-dose ASA therapy, the combination of naproxen plus ASA would increase the GI risk, and therefore, the addition of a gastroprotective agent such as a PPI should be considered.
Long-term NSAID therapy can be more complex in patients with high GI risk. Testing for and eradicating Helicobacter pylori in patients at high risk of NSAID-related GI bleeding should be considered but will be insufficient without ongoing gastroprotection. 57, [136] [137] [138] [139] In these patients, if cardiovascular risk is low, a COX-2 alone or a tNSAID with a PPI appear to offer similar protection from recurrent GI bleeding, but this protection is incomplete. Therefore, for patients at very high risk of upper GI events, a combination of a COX-2 plus a PPI may offer the best GI safety profile. When both GI and cardiovascular risks are high, the optimal strategy is to avoid NSAID therapy if at all possible. If the NSAID therapy is deemed necessary, then the clinician must prioritize the cardiovascular and GI risks, recognizing that these patients are likely taking ASA for their cardiovascular risk. If GI risk is the primary concern (ie, a very high-risk GI patient), a COX-2 plus a PPI is recommended. If the primary concern is cardiovascular risk, naproxen plus a PPI in patients on ASA would be preferred; however, GI risk should be closely monitored, as this strategy carries a higher GI risk than a COX-2 plus a PPI in patients on ASA. 135 
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